Back to Search
Start Over
Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease
- Source :
- British Journal of Haematology. 139:434-438
- Publication Year :
- 2007
- Publisher :
- Wiley, 2007.
-
Abstract
- Impaired bone formation contributes to the lack of bone healing in multiple myeloma and there is a need for agents with bone anabolic properties to reverse the bone deficit in patients. Bortezomib, a proteasome inhibitor with antitumour efficacy in myeloma patients, enhanced new bone formation in mouse calvarial cultures; this effect was blocked by dickkopf 1(Dkk1), an antagonist of Wnt signalling implicated in myeloma bone disease. Bortezomib inhibited Dkk1 expression in calvariae and bone marrow-derived stromal cells, suggesting a novel mechanism by which bortezomib exerts its effects in bone. Clinical trials in patients with myeloma bone disease are needed to validate these results.
- Subjects :
- musculoskeletal diseases
medicine.medical_specialty
Hematology
Bone disease
Bortezomib
Osteoblast
Bone healing
Biology
medicine.disease
Endocrinology
medicine.anatomical_structure
DKK1
immune system diseases
hemic and lymphatic diseases
Internal medicine
medicine
Cancer research
Proteasome inhibitor
Multiple myeloma
medicine.drug
Subjects
Details
- ISSN :
- 00071048
- Volume :
- 139
- Database :
- OpenAIRE
- Journal :
- British Journal of Haematology
- Accession number :
- edsair.doi...........9c0921330ac5b41acfc1bebc9022c3bf